23ANDME INC

23andMe Inc. specializes in human genomics and personalized health data analytics, leveraging advanced DNA sequencing technologies and bioinformatics platforms to deliver insights derived from large-scale genetic datasets. Their core capabilities include population-scale genetic analysis, variant interpretation, and the development of algorithmic models for trait and disease risk prediction. The company applies machine learning and statistical genetics to process raw genomic data into actionable health reports, with expertise in SNP array analysis, whole-genome data processing, and privacy-preserving data aggregation. Their technical differentiation lies in integrating consumer-facing genetic testing with research-grade data pipelines, enabling scalable genomic research while maintaining strict data governance protocols. Award history is not available to infer specific agency engagements or contract performance. Consequently, no verifiable agency experience can be described. The primary NAICS code 541715 reflects research and development in the physical, engineering, and life sciences, indicating that 23andMe operates as a life sciences R&D firm focused on genetic data interpretation and biotechnology innovation. Their market positioning centers on consumer genomics and direct-to-consumer health analytics, with vertical specialization in personalized medicine, pharmacogenomics, and population genetics research. 23andMe Inc. is structured as a limited liability company (2L) headquartered in Sunnyvale, California. The company holds no government certifications, and its operations are primarily commercial, with no publicly verifiable federal contracting activity. While it engages in scientific research with potential government relevance, its current government market presence cannot be confirmed based on available data.